Oral hairy leukoplakia: a clinical indicator of immunosuppression
- Oral lesions among HIV seropositive individuals in an era of generic HAART: markers of HAART efficacy? Vasudevan, Janani; Sivasankar, Vaishnavi; Rao, Umadevi K.; Kumarasamy, Nagalingeswaran; Ranganathan, Kannan // BMC Infectious Diseases;2012 Supplement, Vol. 12 Issue Supplment 1, p1
The article presents a study on the prevalence of oral lesions among HIV seropositive individuals in India. The authors investigate the prevalence of oral lesions among HIV patients on Highly Active Antiretroviral Therapy (HAART). They state that patients under HAART have fewer orals lesions,...
- Prevalence of Oral Manifestations of HIV Infection in Rio De Janeiro, Brazil from 1988 to 2004. Ferreira, Sonia; Noce, Cesar; Júnior, Arley Silva; Gonçalves, Lúcio; Torres, Sandra; Meeks, Valli; Luiz, Ronir; Dias, Eliane // AIDS Patient Care & STDs;Oct2007, Vol. 21 Issue 10, p724
After the introduction of highly active antiretroviral therapy (HAART), several studies have shown a decrease in the prevalence of HIV-associated oral lesions. The goal of this study is to evaluate the prevalence of oral manifestations of HIV in Brazil. A retrospective epidemiologic analysis was...
- Safety, Tolerability and Effectiveness of Generic HAART in HIV-Infected Children in South India. N. Kumarasamy; Kartik K. Venkatesh; Bella Devaleenol; S. Poongulali; S. N. Mothi; Suniti Solomon // Journal of Tropical Pediatrics;Jun2009, Vol. 55 Issue 3, p155
HIV-infected children in resource-limited settings are increasingly gaining greater access to highly active antiretroviral therapy (HAART) but documented longitudinal data remains limited. We aimed to study the clinical and immunological outcomes among 67 South Indian HIV-infected children with...
- Effects of Antiretroviral Agents on Lipid Panels. Song, Jessica C. // AIDS Alert;Dec2007, Vol. 22 Issue 12, p139
The article focuses on the impact of highly active antiretroviral therapy (HAART) on lipid panels of HIV-infected patients.
- South African study shows how few eligible patients start ART. // PharmacoEconomics & Outcomes News;2/20/2010, Issue 597, p2
The article discusses a study by I. V. Bassett et al published in the January 2010 issue of the journal "AIDS" which indicated the number of eligible patients who start antiretroviral therapy (ART) during the first year of being diagnosed with HIV.
- Kaposi Sarcoma—Associated Immune Reconstitution Inflammatory Syndrome: In Need of a Specific Case Definition. Letang, Emilio; Naniche, Denise; Bower, Mark; Miro, Jose M. // Clinical Infectious Diseases;Jul2012, Vol. 55 Issue 1, p157
A letter to the editor is presented in response to the article "Paradoxicalimmune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection by C.J. Achenbach in a 2011 issue.
- Leprosy revealed with HIV treatment. Kemper, Carol A. // Infectious Disease Alert;Jun2007, Vol. 26 Issue 9, p107
The article reports on the worsening cases of previously unrecognized leprosy among human immunodeficiency virus (HIV) positive persons who are receiving highly active antiretroviral therapy (HAART). It says that approximately 300,000 new cases of leprosy are being diagnosed, mostly in Brazil,...
- Alteration in Lipid Profile in Treatment-Naive HIV-Infected Patients and Changes Following HAART Initiation in Haryana. Singh, Jagjeet; Verma, Monica; Ghalaut, Pratap Singh; Verma, Renuka; Soni, Abhishek; Ghalaut, Veena Singh // Journal of Endocrinology & Metabolism;2014, Vol. 4 Issue 1/2, p25
Background: Abnormalities of lipid metabolism are common in human immunodeficiency virus (HIV)-infected patients and tend to be accentuated in those receiving highly active antiretroviral therapy (HAART). However, data on lipid profile of treatmentnaive HIV-infected patients in India are...
- DRV/r monotherapy switch could save Spain â‚¬22 million. // PharmacoEconomics & Outcomes News;1/8/2011, Issue 619, p10
The article focuses on a study which examined the cost efficiency of switching from HAART to darunavir with ritonavir (DRV/r) monotherapy for patients with HIV infection in Spain.